La RETE ONCOLOGICA del PIEMONTE e della VALLE D AOSTA: NOVITÀ e CONTROVERSIE ASCO giugno Dr.ssa Gloria Borra SC Oncologia

Transcript

1 La RETE ONCOLOGICA del PIEMONTE e della VALLE D AOSTA: NOVITÀ e CONTROVERSIE ASCO giugno 2015 Dr.ssa Gloria Borra SC Oncologia A.O.U Maggiore della Carità Novara

2 Adiuvante

3 [TITLE]

4 BRCA in adiuvante

5 Abstracts Presented By Mark Socinski at 2015 ASCO Annual Meeting

6 NCCN Guidelines Version NSCLC Presented By Mark Socinski at 2015 ASCO Annual Meeting

7 Adjuvant Chemotherapy in Early Stage NSCLC Presented By Mark Socinski at 2015 ASCO Annual Meeting

8 BRCA1 and 2 Presented By Mark Socinski at 2015 ASCO Annual Meeting

9 Customized BRCA1 Adjuvant Treatment in Stage II-II NSCLC (SCAT) Presented By Mark Socinski at 2015 ASCO Annual Meeting

10 Customized BRCA1 Adjuvant Treatment in Stage II-II NSCLC (SCAT) Presented By Mark Socinski at 2015 ASCO Annual Meeting

11 Results/1 (cut-off March 15th 2015): Overall survival Presented By Mark Socinski at 2015 ASCO Annual Meeting

12 Results/3: DFS and OS High-BRCA1 levels Presented By Mark Socinski at 2015 ASCO Annual Meeting

13 Results/4: DFS and OS Low BRCA1 levels Presented By Mark Socinski at 2015 ASCO Annual Meeting

14 Conclusions Presented By Bartomeu Massuti at 2015 ASCO Annual Meeting

15 So what can we conclude from this study and what are the issues? Presented By Mark Socinski at 2015 ASCO Annual Meeting

16 Early stage

17 Abstracts Presented By Mark Socinski at 2015 ASCO Annual Meeting

18 PROCLAIM: Study Design Presented By Mark Socinski at 2015 ASCO Annual Meeting

19 PROCLAIM: Study Design Presented By Mark Socinski at 2015 ASCO Annual Meeting

20 PROCLAIM: Study Design Presented By Mark Socinski at 2015 ASCO Annual Meeting

21 Slide 18 Presented By Mark Socinski at 2015 ASCO Annual Meeting

22 PROCLAIM Presented By Mark Socinski at 2015 ASCO Annual Meeting

23 So what can we PROCLAIM?<br /> Presented By Mark Socinski at 2015 ASCO Annual Meeting

24 Questions Raised Presented By Mark Socinski at 2015 ASCO Annual Meeting

25 Nivolumab

26 Nivolumab Mechanism of Action Presented By David Spigel at 2015 ASCO Annual Meeting

27 CheckMate 017 (NCT ) - Study Design Presented By David Spigel at 2015 ASCO Annual Meeting

28 Overall Survival Presented By David Spigel at 2015 ASCO Annual Meeting

29 Progression-Free Survival Presented By David Spigel at 2015 ASCO Annual Meeting

30 Objective Response Rate Presented By David Spigel at 2015 ASCO Annual Meeting

31 OS and PFS by PD-L1 Expression Presented By David Spigel at 2015 ASCO Annual Meeting

32 OS by PD-L1 Expression Presented By David Spigel at 2015 ASCO Annual Meeting

33 ORR by PD-L1 Expression Presented By David Spigel at 2015 ASCO Annual Meeting

34 Summary Presented By David Spigel at 2015 ASCO Annual Meeting

35 Atezolizumab

36 Atezolizumab is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1 Presented By Alexander Spira at 2015 ASCO Annual Meeting

37 PD-L1 Expression on TC and IC is a Potential Predictive Biomarker for Atezolizumab in NSCLC Presented By Alexander Spira at 2015 ASCO Annual Meeting

38 POPLAR: A Randomized All-comer Phase II Study Presented By Alexander Spira at 2015 ASCO Annual Meeting

39 POPLAR: All Patient Efficacy<br />ITT interim OS (N = 287) Presented By Alexander Spira at 2015 ASCO Annual Meeting

40 POPLAR: PD-L1 Expression Subgroups<br />TC3 or IC3 interim OS (n = 47) Presented By Alexander Spira at 2015 ASCO Annual Meeting

41 POPLAR: PD-L1 Expression Subgroups<br />TC2/3 or IC2/3 interim OS (n = 105) Presented By Alexander Spira at 2015 ASCO Annual Meeting

42 POPLAR: PD-L1 Expression Subgroups<br />TC1/2/3 or IC1/2/3 interim OS (n = 195) Presented By Alexander Spira at 2015 ASCO Annual Meeting

43 POPLAR: PD-L1 Expression Subgroups<br />TC0 and IC0 interim OS (n = 92) Presented By Alexander Spira at 2015 ASCO Annual Meeting

44 Summary Presented By Alexander Spira at 2015 ASCO Annual Meeting

45